Ultimovacs provides update on Phase II NIPU trial evaluating

The central independent review concluded that the NIPU study did not meet the primary endpoint of progression-free survival . However, a statistically significant improvement in PFS for... | June 7, 2023

Related Keywords

Oslo , Norway , Germany , Australia , Spain , Bristol Myers Squibbs , Bristol Myers Squibb , Halle University , International Agency For Research On Cancer Globocan , Professor At Oslo University Hospital , Oslo University Hospital , Principal Investigator , Oslo University , Carlos De Sousa , Chief Executive Officer , International Agency , Human Leukocyte Antigen , Ultimovacs Asa Stock Exchange , News , Information , Press Release , Independent , Review , Oncluded , Hat , Kid , Lot , Feet , The , Primary , Ndpoint , F , Survival , Statistically , Significant , Improvement , N , Fs Ulti No0010851603 ,